New Weight Loss Drugs on the Horizon
Acomplia was a ground-breaking new breed of medication which targeted
the body’s little understood endocannabinoid system when it was
launched in the UK last June but it could soon have one or more rivals.
Both Merck and Pfizer have similar drugs in Phase III clinical trials
which are said to be producing very promising results. Merck has
already announced that it intends to apply for regulatory approval in
2008 and it is believed that Pfizer will be aiming to seek approval at
around the same time. There is another drug which works in a similar
way to Acomplia under development by Bristol Myers Squibb but it is
believed that the development of this product is significantly behind
those of Merck and Pfizer.
» Leave a comment
- Your E-mail address is never displayed. If you enter it, it will only be visible to the blog author
- The line and paragraph breaks automatically
